APT Department Seminar: Pascal Bernatchez
Genetic aortopathies and muscular dystrophies are two seemingly unrelated groups of diseases with poor management options. Our laboratory has recently shown that cardiovascular medications that target the LDL-cholesterol synthesis pathways and the vasculature, particularly the endothelium, offer untapped therapeutic potential for patients afflicted by these conditions. Using classic and molecular pharmacology principles, we study how these medications mediate their unexpected effects and whether better treatments can be translated to the clinic.